Navigation Links
Mach One Executes Definitive Agreement to Acquire Biopharmaceutical Design & Engineering Firm
Date:2/11/2009

BELGIUM, WI, Feb. 11 /PRNewswire-FirstCall/ -- Mach One Corporation (Pink Sheets: MNCN), a global health company that develops biotechnology based solutions that produce positive, long term benefit to the agricultural and consumer markets, announced today that it has executed its definitive agreement to acquire Modular Process Constructors LLC.

The purchase price of $500,000 in the form of Convertible Preferred Stock with a conversion price of .50 per share will allow Mach One to bring in house the engineering and design experience needed to roll out its capacity expansion on a national basis -- plans that include up to 17 facilities nationally. Bringing needed in-house expertise along with the ability to engineer and design systems for world class customers, Mach One takes an important step in building their internal expertise for organic growth.

Monte B. Tobin, Chairman and Chief Executive Officer of Mach One, said, "We welcome the expertise to facilitate expansion of our business model internally combined with key engineering experts who are able to work externally with world class customers in the biopharmaceutical industry."

"This is yet another major building block Mach One is leveraging to advance our business plan through our new director, Tad M. Ballantyne. Tad joined the board with our recent acquisition of Pacific Rim Foods Ltd. and is also Managing Director of the parent company of Modular Process Constructors LLC. Through these key associations, Mr. Ballantyne has provided both capital and technology to Mach One in the execution of our business model. It's important to see that our acquisition strategy is accretive to our core business by the addition of not only revenues and assets, but of highly specialized knowledge and expertise," added Tobin.

About Mach One Corporation:

Mach One Corporation (www.machonecorp.com) is a global health company that provides biotechnology based solutions to help address one of the world's most pressing and costly needs -- positive, long-term health and longevity benefits for disease-threatened animals of large commercial operations. Mach One provides broad spectrum immunoglobulin and nutraceutical products that offer a new level of cost effectiveness, improved health and ease of treatment -- with an initial focus on the dairy industry. Mach One intends to fully leverage the potential of its breakthrough solutions -- breakthroughs that one day will also include consumer applications.

Cautionary Statement: This news release may include certain "Forward-looking statements" within the meaning of Section 21E of the United States Securities Exchange Act, as amended. All statements, other than statements of historical fact, included in this release are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. This notice expressly qualifies all forward-looking statements in this release.


'/>"/>
SOURCE Mach One Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
2. Diamyd Strengthens Financial Position and Executes a Fully Subscribed Direct Placement
3. Rosetta Genomics Executes Binding Term Sheet to Acquire U.S. CLIA-Certified Lab to Expedite Commercialization of Diagnostic Tests
4. New Edition of Definitive Resource in Tissue Engineering Released Today
5. Arrow International Files and Mails Definitive Proxy Materials
6. IsoTis Files Definitive Proxy Statement
7. Acorn Acquisition Corp Announces Definitive Agreement to Acquire Lumen Medical Inc.
8. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
9. Nabi Biopharmaceuticals Announces Mailing of Definitive Proxy Statement and Release Date of Third Quarter 2007 Financial Results
10. Advanced Life Sciences Enters Into Definitive Securities Purchase Agreements for $20 Million with New and Existing Institutional Investors
11. Bayer HealthCare Affiliate MEDRAD and Possis Medical Sign Definitive Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):